The Manila Times

Quoin Pharmaceuticals Announces FDA Grants Fast Track Designation for QRX003 for the Treatment of Netherton Syndrome

Fast Track Designation facilitates development and expedites regulatory review of therapies addressing serious conditions ...

Quoin Wins FDA Fast Track for QRX003 in Netherton

Detailed price information for Quoin Pharmaceuticals Ltd ADR (QNRX-Q) from The Globe and Mail including charting and trades.

Quoin Pharmaceuticals, Inc.: Quoin Pharmaceuticals Announces FDA Grants Fast Track Designation for QRX003 for the Treatment of Netherton Syndrome

Fast Track Designation facilitates development and expedites regulatory review of therapies addressing serious conditions with significant unmet medical need - - QRX003 lotion (4%) currently being ...

Step by step: What your feet can reveal about your body

Lorraine Wylie on why feet can a reveal a lot about an individual’s state of health ...
GlobalData on MSN

Aisa Pharma reports positive results for AISA-021

The study included 64 patients and was conducted in two segments.
Pharmabiz

Aisa Pharma announces positive results from phase 2 RECONNOITER trial of cilnidipine in patients with systemic sclerosis-associated Raynaud's phenomenon

Aisa Pharma announces positive results from phase 2 RECONNOITER trial of cilnidipine in patients with systemic sclerosis-associated Raynaud's phenomenon: Boston Monday, March 9, 2 ...
Medical Dialogues

Hyaluronic Acid Fillers: A Promising Option for systemic sclerosis and Morphea: Study

A new study published in the journal of Autoimmunity Reviews that Hyaluronic acid (HA) fillers seem to be a safe, minimally invasive treatment for improving both functional and aesthetic ...
Nature

Cosmetic scientists strive to unpack skin regeneration

Understanding how skin regenerates following aesthetic procedures such as microneedling and laser resurfacing could offer new approaches to skin care. When it comes to treating sun damage, acne scars, ...